What's Going On With Abivax Stock On Thursday?

Abivax stock rose 3.46% on Thursday despite concerns following the release of Phase 3 trial data for obefazimod in ulcerative colitis. While the drug met primary endpoints with remission rates exceeding 50%, reported cancer cases during the trial have raised safety concerns among investors. The stock trades below its moving averages, with momentum indicators suggesting weakness.